期刊
ALZHEIMERS & DEMENTIA
卷 12, 期 1, 页码 60-64出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2015.12.003
关键词
Alzheimer's; Research & development; Clinical trials; Dementia; Attrition; Amyloid hypothesis
资金
- National Institute for Health Research [NF-SI-0513-10134, NF-SI-0508-10123] Funding Source: researchfish
- MRC [MR/L023784/1, MC_U105184291] Funding Source: UKRI
- Medical Research Council [MR/L023784/1, MC_U105184291] Funding Source: Medline
The success rate of the pharmaceutical research and development (R&D) for dementia drugs has been abysmally low, in the last two decades. Also low has been the number of pipeline drugs in development, compared to other therapy areas. However, the rationale of early terminations has not been reported in the majority of trials. These are key findings of the recently published pharmaceutical pipeline analysis by the UK-based Office of Health Economics (OHE). Our understanding of main challenges include (1) the significant gaps of knowledge in the nosology and complexity of the underpinning biological mechanisms of the commonest, not familial, forms of late onset dementias; (2) low signal-to-noise ratio, notwithstanding the lack of validated biomarkers as entry and/or end-point criteria; (3) recruitment and retention, particularly in the asymptomatic and early disease stages. A number of current and future strategies aimed at ameliorating drug development are outlined and discussed. (C) 2016 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据